Clinical Trials
Institution: Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center
Type: Multi-Center Trial
Purpose:
The purpose of this study is to find the best dose of the investigational drugs guadecitabine and mocetinostat to be given safely and effectively with pembrolizumab immunotherapy in patients with metastatic non-small cell lung cancer. Pembrolizumab works by blocking a molecule called PD-1 that shuts down the immune response. Blocking PD-1 can allow the immune system to detect and attack cancer cells. Guadecitabine and mocetinostat are “epigenetic therapies” that work on certain genes that may be turned on or off in cancer. Pembrolizumab is given intravenously (by vein). Guadecitabine is given by subcutaneous (under the skin) injection, and mocetinostat is taken orally (by mouth).
Dates: August 4, 2017 - July 31, 2020
Disease: Lung Cancer
Contact:
By center:
Memorial Sloan Kettering
Matthew Hellman, MD
[email protected]
646-888-4863
Fox Chase
Hossein Borghaei, MS, DO
[email protected]
888-369-2427 or 215-214-4297
Johns Hopkins
Jarushka Naidoo, MBBCh
[email protected]
410-955-8866
Page last updated: November 17, 2022
